Clik here to view.
Impella RP Flex with SmartAssistによる治療を世界で初めて実施
米マサチューセッツ州ダンバース （ビジネスワイヤ） –アビオメッド（Nasdaq: ABMD）は、右心不全の患者さん向けのアビオメッドの最新心臓ポンプ、Impella RP Flex with...
View ArticleClik here to view.
MTTI Receives Chinese Patent for EVATHERA Technology
WEST CHESTER, Pa. Molecular Targeting Technologies, Inc. (MTTI) announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its...
View ArticleClik here to view.
Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug...
TOKUSHIMA, Japan Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the...
View ArticleClik here to view.
SIMPLEX QUANTUM, Inc. Raises Round of Series A Funding
TOKYO SIMPLEX QUANTUM, Inc. has raised JPY550 million in a round of Series A funding. Simplex Holdings, Inc., along with the Technology Ventures No. 5 Investment Limited Partnership managed by...
View ArticleClik here to view.
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the...
TOKYO & MUNICH, Germany & BASKING RIDGE, N.J. Updated results from the DESTINY-Breast03 phase 3 trial (Abstract #GS2-02) showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a...
View ArticleClik here to view.
Aurion Biotech Appoints Jonathan Sparks, JD, PhD as Chief Legal Officer
SEATTLE, BOSTON & TOKYO Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Dr. Jonathan...
View ArticleClik here to view.
Exscientia在ESMO免疫肿瘤学年度大会上展示针对EXS-21546的新型免疫肿瘤学生物标志物
奥地利维也纳和英格兰牛津 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)今天强调了新数据，以识别更有可能对其A2A受体拮抗剂EXS-21546...
View ArticleClik here to view.
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy...
SANTA MONICA, Calif. & TOKYO Kite Pharma, Inc., a Gilead Company, (hereafter Kite) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) today jointly announced the revision of their 2017...
View ArticleClik here to view.
Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing...
SAN DIEGO & DUBLIN Crown Bioscience, Inc, a JSR Life Sciences Company, and ERS Genomics Limited (‘ERS’) have signed a global license agreement for access to the foundational CRISPR/Cas9 patent...
View ArticleClik here to view.
Crown Bioscience と ERS Genomics がグローバルでゲノム編集に関わる CRISPR/Cas9 のライセンス契約を発表
米国サンディエゴおよびアイルランド・ダブリン （ビジネスワイヤ） — JSRライフサイエンスの Crown Bioscience と ERS Genomics 社（以下、ESR）は ESR が保有する CRISPR/Cas9 の関連特許利用に関わるグローバルライセンス契約を締結し、グローバルでのCRISPR/Cas9 を用いたゲノム編集に関わる完全なライセンスを受けることになりました。...
View ArticleClik here to view.
冠科生物宣布与ERS Genomics签订基因编辑专利CRISPR/Cas9的全球性许可协议
美国圣地亚哥和爱尔兰都柏林 (美國商業資訊)– 冠科生物（JSR生命科学集团旗下子公司）宣布与ERS Genomics Limited（简称“ERS”）签订了一份授权使用ERS的CRISPR/Cas9原始专利许可协议，这意味着冠科生物能够在全球全权使用CRISPR/Cas9进行基因编辑研究。 本新聞稿包含多媒體資訊。完整新聞稿請見此：...
View ArticleClik here to view.
エクセンシア、ESMO免疫腫瘍学会の年次総会でEXS-21546用の新規がん免疫療法バイオマーカーを発表
オーストリア・ウィーン & 英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq:...
View ArticleClik here to view.
NRDL Inclusion Offers Substantial Opportunities for Innovative, Clinically...
WALTHAM, Mass. Trinity Life Sciences, a leader in global life sciences commercialization solutions, reports that inclusion on the National Reimbursement Drug List (NRDL) offers substantial...
View ArticleClik here to view.
Bertis Announces Research Results of AI-based Disease Diagnosis Model in the...
SEONGNAM, South Korea Bertis, a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced research results of AI-based disease diagnosis...
View ArticleClik here to view.
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients...
TOKYO & MUNICH & BASKING RIDGE, N.J. Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd) showed encouraging and durable efficacy in patients with...
View ArticleClik here to view.
知临集团宣布发行 2023 年到期的 300 万美元可转换票据
纽约、伦敦和巴黎 (美国商业资讯)– 知临集团有限公司（纳斯达克股票代码：APM，巴黎泛欧证券交易所股票代码：APM）（“知临集团”或“知临”），一家致力于满足肿瘤、自身免疫性疾病和传染病领域未被满足的医疗需求的临床阶段生物制药公司，今天宣布私募发售本金总额为300万美元 的2023年到期的可转换票据（“票据”），将用作公司日常运营和临床计划资金的一部分。 该票据将由Aenco...
View ArticleClik here to view.
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that it will present 15 company-sponsored abstracts at the 64th American Society of Hematology (ASH) Annual Meeting...
View ArticleClik here to view.
Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a...
BOSTON & DAEJEON, South Korea Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced the presentation...
View ArticleClik here to view.
SaVia Health Raises $8.5 Million Seed Round to Optimize Patient Care Pathways
SALT LAKE CITY SaVia Health, a clinician-led healthcare SaaS company that creates and embeds patient care processes alongside electronic medical records (EMR), announced it raised an $8.5 million...
View ArticleClik here to view.
GIセルがオプティアム・バイオテクノロジーズと契約を締結
韓国・城南 （ビジネスワイヤ） — GIセルは本日、オプティアム・バイオテクノロジーズ株式会社（日本）と研究ライセンス／オプション契約を締結したと発表しました。契約に従い、オプティアム・バイオテクノロジーズはGIセルに対し、オプティアム・バイオテクノロジーズのEumbody...
View Article